Number of patients according to chemotherapy protocol.
| Stage | AD-COMP | ALL-type regimena) | LSA2-L2b) | NY |
POG regimenc) | |
|---|---|---|---|---|---|---|
| N | ||||||
| B-LBL | I | 1 | 3 | 0 | 2 | 1 |
| II | 0 | 1 | 0 | 1 | 2 | |
| III | 0 | 0 | 0 | 1 | 1 | |
| IV | 1 | 2 | 1 | 3 | 1 | |
| Total | 2 | 6 | 1 | 7 | 5 | |
| T-LBL | II | 0 | 1 | 0 | 4 | 1 |
| III | 2 | 5 | 3 | 8 | 0 | |
| IV | 1 | 2 | 2 | 7 | 1 | |
| Total | 3 | 8 | 5 | 19 | 2 | |
| Unknown | I | 1 | 0 | 0 | 0 | 0 |
| III | 0 | 0 | 0 | 1 | 0 | |
| IV | 0 | 0 | 1 | 0 | 0 | |
| Total | 6 (9.8%) | 14 (23.0%) | 7 (11.5%) | 27 (44.3%) | 7 (11.5%) | |
a)CCG-1882 or Korean multicenter high-risk ALL protocol; b)CCG-106B, CCG-1901, or CCG-5941; c)POG 9219, POG-9317, POG-9404, or POG-9406. There was no statistically significant difference in age, sex, immunophenotypes, stages, initial CNS or BM involvement between patients of the NY protocol group, and those in the ALL-type protocol group.
Abbreviations: AD-COMP, addition of daunorubicin and asparaginase to the basic COMP protocol; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma; NY, New York; POG, Pediatric Oncology Group.
Blood Res 2020;55:262~274 https://doi.org/10.5045/br.2020.2020220
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd